TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma
Clinical trial NCT04217473 · COMPLETED
Trial details
- NCT number
- NCT04217473
- Sponsor
- TILT Biotherapeutics Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-26
- Primary completion
- 2023-12-12
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.